Form 4: Amphastar Director Richard Prins Reports Equity Changes

Director Richard K. Prins reported a gift of common stock and the acquisition of restricted stock units and options in Amphastar Pharmaceuticals.

Summary

• Director Richard K. Prins gifted 1,500 shares of common stock on August 19, 2024.
• The director was granted 8,143 restricted stock units (RSUs) on June 1, 2026.
• The director was granted 17,365 stock options with an exercise price of $18.42 on June 1, 2026.
• Following these transactions and a reconciliation adjustment, the director's beneficial ownership stands at 37,598 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine disclosure of director equity activity with no material impact on the company's financial outlook.

Positives

• Director maintains a significant equity stake in the company.
• Equity-based compensation aligns director interests with long-term shareholder value.

Negatives

• The filing includes a reconciliation adjustment reducing the reported beneficial ownership by 4,228 shares.

Risks

• Market volatility affecting the value of equity-based compensation.
• Potential for future dilution if stock options are exercised.

Future Outlook

The RSUs and stock options granted are scheduled to vest on June 1, 2027, indicating a long-term retention incentive for the director.

Industry Context

StockSavvy.ai notes that director equity grants are standard practice in the pharmaceutical industry to ensure alignment between board oversight and corporate performance.

Comparison to Industry Standards

• The use of RSUs and stock options as part of director compensation is consistent with standard corporate governance practices for mid-cap pharmaceutical companies.
• The vesting period of one year is standard for annual director equity grants.

Stakeholder Impact

• Minimal impact on shareholders as these are standard director compensation and personal gift transactions.

Next Steps

• Vesting of RSUs and stock options on June 1, 2027.

Key Dates

Keywords

Amphastar Pharmaceuticals, AMPH, Form 4, Insider Trading, Director Compensation, Equity Ownership